Nevro Corp. Financial Results and Strategic Acquisition Plans
Nevro Corp. (NYSE: NVRO), a leader in innovative medical device solutions aimed at alleviating chronic pain, recently announced its financial results for the fourth quarter and the entire fiscal year of 2024. The company continues to focus on enhancing its balance sheet while aligning its growth strategy with the planned acquisition by Globus Medical (NYSE: GMED).
Strategic Acquisition Announcement
On a significant note, Nevro Corp. and Globus Medical revealed a definitive agreement for an acquisition valued at approximately $250 million, with each share priced at $5.85. This strategic move is set to finalize in the second quarter of 2025, pending approval from shareholders, along with regulatory conditions. Nevro’s president and CEO, Kevin Thornal, expressed optimism about the merger, highlighting the potential to enhance their mission of alleviating chronic pain for patients globally.
2024 Business Highlights
Throughout the quarter, Nevro accomplished several notable releases and improvements:
- Nevro successfully rolled out full market availability of the HFX iQ™ device, featuring the innovative HFX AdaptivAI™ technology aimed at delivering personalized pain management.
- In January 2025, the HFX iQ spinal cord stimulation (SCS) system was launched in select European markets after securing CE Mark certification in November 2024.
- Recent research published in the Journal of Pain Research emphasized the efficacy of Nevro's 10 kHz high-frequency SCS therapy in providing durable pain relief, particularly for patients suffering from diabetic neuropathy.
- Further findings shared in Medical Devices: Evidence and Research illustrated the superior advantages of Nevro's SI Joint Fusion System over traditional fixation methods.
Fourth-Quarter 2024 Financial Results
Nevro reported worldwide revenues of $105.5 million for the fourth quarter of 2024, marking a decrease of 9.1% from $116.2 million in the same quarter of 2023. U.S. revenues account for $91.4 million, down from $101.5 million in the prior year. Meanwhile, international revenue saw a slight dip to $14.1 million amidst competitive market conditions.
Examining gross profits, Nevro recorded a gross profit of $65.9 million, equating to a gross margin of 62.5%, which is lower than the 70.1% margin from the previous year. Operating expenses surged to $117.3 million, fueled by a significant goodwill impairment charge and other related costs.
Full-Year Financial Overview
Over the course of 2024, Nevro’s total revenue reached $408.5 million, down 3.9% year-on-year. The company also noted an adjusted EBITDA loss of $13.6 million, a slight improvement from a loss of $17.7 million recorded in 2023. Nevro remains committed to improving operational efficiency and exploring avenues for revenue growth as part of its forward-looking strategy, especially in preparation for the acquisition by Globus Medical.
Key Insights from Nevro’s Financial Guidance
Due to the ongoing acquisition process, Nevro will not be issuing further guidance for the fiscal year 2025. The focus remains on ensuring a seamless transition and maximizing value for shareholders while maintaining operational momentum.
About Nevro Corp.
Nevro Corp. is dedicated to providing advanced solutions for chronic pain management. The company’s flagship HFX spinal cord stimulation platform is known for its effectiveness in treating chronic pain, which includes services tailored for patients dealing with sacroiliac joint pain and diabetic neuropathy. The acquisition by Globus Medical is anticipated to enhance Nevro’s capabilities in this vital area.
Investors can find vital information about Nevro in the "Investor Relations" section of its official website.
Frequently Asked Questions
What is the significance of the Globus Medical acquisition for Nevro?
The acquisition is expected to enhance Nevro’s capabilities in pain management, allowing for greater resource utilization and clinical synergies.
How did Nevro’s revenues change in 2024?
Nevro experienced a 3.9% decrease in total revenue for 2024 compared to the previous year, reflecting challenges in the market.
What products does Nevro offer for chronic pain management?
Nevro’s HFX spinal cord stimulation platform, including the HFX iQ system, is notable for its advanced pain management technology and support services.
What challenges did Nevro face in Q4 of 2024?
Major challenges included decreased revenues and increased operating expenses, particularly linked to an impairment charge impacting profitability.
What could investors expect from Nevro moving forward?
Investors can anticipate enhanced operational processes post-acquisition, aiming for improved financial health and product offerings in pain management.
